PRCT vs. SNN, PEN, STVN, GKOS, BLCO, INSP, NARI, IRTC, NVST, and TMDX
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), Envista (NVST), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
PROCEPT BioRobotics vs.
Smith & Nephew (NYSE:SNN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.
Smith & Nephew has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -50.07%. Smith & Nephew's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.
In the previous week, PROCEPT BioRobotics had 5 more articles in the media than Smith & Nephew. MarketBeat recorded 12 mentions for PROCEPT BioRobotics and 7 mentions for Smith & Nephew. PROCEPT BioRobotics' average media sentiment score of 0.82 beat Smith & Nephew's score of 0.57 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.
Smith & Nephew received 409 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 68.97% of users gave PROCEPT BioRobotics an outperform vote while only 54.29% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Smith & Nephew currently has a consensus price target of $27.00, indicating a potential downside of 3.83%. PROCEPT BioRobotics has a consensus price target of $94.29, indicating a potential upside of 62.28%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Smith & Nephew.
Smith & Nephew has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
25.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
PROCEPT BioRobotics beats Smith & Nephew on 10 of the 18 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
This page (NASDAQ:PRCT) was last updated on 3/21/2025 by MarketBeat.com Staff
